Cipla vs Apollohosp Q4 FY25

Cipla delivered a solid Q4 FY25 with revenue of INR 6,730 crore (+9% YoY) and EBITDA margin of 22.8% (+150bps YoY), driven by strong performance across One India (+8% YoY), North America ($221M quarterly revenue), and EMU (+16% YoY). PAT stood at INR 1,222 crore. The company guided FY26 EBITDA margin of 23.5%-24.5%, reflecting confidence despite generic Revlimid exclusivity loss. Key growth drivers include respiratory pipeline (Advair launch in FY26, six respiratory ANDAs filed), peptide launches (two to three in FY26), and Nano Paclitaxel/Nilotinib approvals. One India chronic mix improved to 61.5%. Risk: Generic Revlimid compression could pressure U.S. revenue and margins in coming quarters.

Guidance read

FY26 EBITDA margin guidance of 23.5%-24.5%: Management guided EBITDA margin in the range of 23.5%-24.5% for FY26, reflecting confidence despite Revlimid exclusivity loss. Advair launch expected in FY26: Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization. Two to three peptide launches in FY26: Cipla aims to launch two to three peptide assets in FY26, with one expected to be a large asset. U.S. revenue run rate of ~$220 million for Q1 FY26: Management indicated U.S. revenue for the next quarter is expected to be around $220 million, factoring in Revlimid compression.

Risk read

Key risks include Generic Revlimid exclusivity loss — Revlimid exclusivity ends in FY26, which will compress revenue and margins in the U.S. business.; Lanreotide supply normalization uncertainty — While supplies are resuming, the timeline to regain previous market share is uncertain and may take time.; U.S. tariff and regulatory risks — Potential U.S. tariffs on pharma imports and executive orders on pricing could impact the business, though management sees limited near-term impact.; Execution risk on peptide and respiratory pipeline — Delays in approvals or commercial launches of key pipeline assets (peptides, Advair) could affect growth trajectory..

Promise ledger

Of 2 tracked promises, management 0 met, 0 close, 2 missed.

Apollo Hospitals delivered a strong Q4 FY25 with consolidated revenue of INR 5,592 crore (+13% YoY) and PAT of INR 390 crore (+54% YoY). Healthcare services revenue grew 10% to INR 2,822 crore, impacted by ~2% from Bangladesh patient flow disruptions. Occupancy was 67% (metro 70%), ARPOB rose 7% to INR 63,569. Apollo HealthCo revenue grew 17% to INR 2,376 crore, with digital losses narrowing to INR 80 crore (vs INR 111 crore last year). AHLL EBITDA grew 32% to INR 47 crore. Management guided for low-to-mid teens organic hospital growth in FY26, with new bed additions (4,300 beds over 3-4 years) starting to contribute meaningfully from FY27. The digital business targets cash break-even between Q3-Q4 FY26. Key risks include continued Bangladesh headwinds in Q1 FY26 and margin dilution from new hospital ramp-ups.

Guidance read

Healthcare services low-to-mid teens organic growth in FY26: Management expects organic revenue growth of low-to-mid teens for healthcare services in FY26, with new hospitals contributing from FY27. Digital business cash break-even by Q3-Q4 FY26: Apollo 24/7 is on track to achieve cash break-even between Q3 and Q4 of FY26, driven by cost reduction and revenue growth. HealthCo combined revenue target of INR 24,000-25,000 crore by FY27: Apollo HealthCo (including Keimed) targets revenue of INR 24,000 crore in FY27, with exit run rate crossing INR 25,000 crore. HealthCo blended EBITDA margin of 7%+ by FY27: Blended EBITDA margin for HealthCo (including Keimed) is expected to exceed 7% by FY27, driven by digital break-even and margin expansion.

Risk read

Key risks include Bangladesh patient flow disruption — Continued impact from reduced Bangladesh patient inflows, expected to persist through Q1 FY26, affecting hospital revenue and margins.; Margin dilution from new hospital ramp-up — New hospitals in Gurgaon, Pune, Kolkata, and Hyderabad will incur initial losses, potentially compressing healthcare services margins by ~140 bps in FY26.; Quick commerce competition in pharmacy — Rapid delivery platforms (10-minute) are gaining share in OTC/FMCG, though Apollo's 19-minute proposition and RX focus mitigate impact.; Keimed merger integration risks — The Keimed merger process is expected to take 15 months; integration challenges could delay synergy realization..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.